Biologically targeted magnetic hyperthermia

Potential and limitations

David Chang, May Lim, Jeroen A. C. M. Goos, Ruirui Qiao, Yun Yee Ng, Friederike M. Mansfeld, Michael Jackson, Thomas P. Davis, Maria Kavallaris

Research output: Contribution to journalReview ArticleResearchpeer-review

20 Citations (Scopus)

Abstract

Hyperthermia, the mild elevation of temperature to 40-43°C, can induce cancer cell death and enhance the effects of radiotherapy and chemotherapy. However, achievement of its full potential as a clinically relevant treatment modality has been restricted by its inability to effectively and preferentially heat malignant cells. The limited spatial resolution may be circumvented by the intravenous administration of cancer-targeting magnetic nanoparticles that accumulate in the tumor, followed by the application of an alternating magnetic field to raise the temperature of the nanoparticles located in the tumor tissue. This targeted approach enables preferential heating of malignant cancer cells whilst sparing the surrounding normal tissue, potentially improving the effectiveness and safety of hyperthermia. Despite promising results in preclinical studies, there are numerous challenges that must be addressed before this technique can progress to the clinic. This review discusses these challenges and highlights the current understanding of targeted magnetic hyperthermia.

Original languageEnglish
Article number831
Number of pages20
JournalFrontiers in Pharmacology
Volume9
DOIs
Publication statusPublished - 2 Aug 2018

Keywords

  • Cancer therapy
  • Iron oxide nanoparticles
  • Magnetic hyperthermia
  • Magnetic nanoparticles
  • Targeted therapy

Cite this

Chang, D., Lim, M., Goos, J. A. C. M., Qiao, R., Ng, Y. Y., Mansfeld, F. M., ... Kavallaris, M. (2018). Biologically targeted magnetic hyperthermia: Potential and limitations. Frontiers in Pharmacology, 9, [831]. https://doi.org/10.3389/fphar.2018.00831
Chang, David ; Lim, May ; Goos, Jeroen A. C. M. ; Qiao, Ruirui ; Ng, Yun Yee ; Mansfeld, Friederike M. ; Jackson, Michael ; Davis, Thomas P. ; Kavallaris, Maria. / Biologically targeted magnetic hyperthermia : Potential and limitations. In: Frontiers in Pharmacology. 2018 ; Vol. 9.
@article{6439ba2901a849d8b157c47a012b2fc4,
title = "Biologically targeted magnetic hyperthermia: Potential and limitations",
abstract = "Hyperthermia, the mild elevation of temperature to 40-43°C, can induce cancer cell death and enhance the effects of radiotherapy and chemotherapy. However, achievement of its full potential as a clinically relevant treatment modality has been restricted by its inability to effectively and preferentially heat malignant cells. The limited spatial resolution may be circumvented by the intravenous administration of cancer-targeting magnetic nanoparticles that accumulate in the tumor, followed by the application of an alternating magnetic field to raise the temperature of the nanoparticles located in the tumor tissue. This targeted approach enables preferential heating of malignant cancer cells whilst sparing the surrounding normal tissue, potentially improving the effectiveness and safety of hyperthermia. Despite promising results in preclinical studies, there are numerous challenges that must be addressed before this technique can progress to the clinic. This review discusses these challenges and highlights the current understanding of targeted magnetic hyperthermia.",
keywords = "Cancer therapy, Iron oxide nanoparticles, Magnetic hyperthermia, Magnetic nanoparticles, Targeted therapy",
author = "David Chang and May Lim and Goos, {Jeroen A. C. M.} and Ruirui Qiao and Ng, {Yun Yee} and Mansfeld, {Friederike M.} and Michael Jackson and Davis, {Thomas P.} and Maria Kavallaris",
year = "2018",
month = "8",
day = "2",
doi = "10.3389/fphar.2018.00831",
language = "English",
volume = "9",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media",

}

Chang, D, Lim, M, Goos, JACM, Qiao, R, Ng, YY, Mansfeld, FM, Jackson, M, Davis, TP & Kavallaris, M 2018, 'Biologically targeted magnetic hyperthermia: Potential and limitations', Frontiers in Pharmacology, vol. 9, 831. https://doi.org/10.3389/fphar.2018.00831

Biologically targeted magnetic hyperthermia : Potential and limitations. / Chang, David; Lim, May; Goos, Jeroen A. C. M.; Qiao, Ruirui; Ng, Yun Yee; Mansfeld, Friederike M.; Jackson, Michael; Davis, Thomas P.; Kavallaris, Maria.

In: Frontiers in Pharmacology, Vol. 9, 831, 02.08.2018.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Biologically targeted magnetic hyperthermia

T2 - Potential and limitations

AU - Chang, David

AU - Lim, May

AU - Goos, Jeroen A. C. M.

AU - Qiao, Ruirui

AU - Ng, Yun Yee

AU - Mansfeld, Friederike M.

AU - Jackson, Michael

AU - Davis, Thomas P.

AU - Kavallaris, Maria

PY - 2018/8/2

Y1 - 2018/8/2

N2 - Hyperthermia, the mild elevation of temperature to 40-43°C, can induce cancer cell death and enhance the effects of radiotherapy and chemotherapy. However, achievement of its full potential as a clinically relevant treatment modality has been restricted by its inability to effectively and preferentially heat malignant cells. The limited spatial resolution may be circumvented by the intravenous administration of cancer-targeting magnetic nanoparticles that accumulate in the tumor, followed by the application of an alternating magnetic field to raise the temperature of the nanoparticles located in the tumor tissue. This targeted approach enables preferential heating of malignant cancer cells whilst sparing the surrounding normal tissue, potentially improving the effectiveness and safety of hyperthermia. Despite promising results in preclinical studies, there are numerous challenges that must be addressed before this technique can progress to the clinic. This review discusses these challenges and highlights the current understanding of targeted magnetic hyperthermia.

AB - Hyperthermia, the mild elevation of temperature to 40-43°C, can induce cancer cell death and enhance the effects of radiotherapy and chemotherapy. However, achievement of its full potential as a clinically relevant treatment modality has been restricted by its inability to effectively and preferentially heat malignant cells. The limited spatial resolution may be circumvented by the intravenous administration of cancer-targeting magnetic nanoparticles that accumulate in the tumor, followed by the application of an alternating magnetic field to raise the temperature of the nanoparticles located in the tumor tissue. This targeted approach enables preferential heating of malignant cancer cells whilst sparing the surrounding normal tissue, potentially improving the effectiveness and safety of hyperthermia. Despite promising results in preclinical studies, there are numerous challenges that must be addressed before this technique can progress to the clinic. This review discusses these challenges and highlights the current understanding of targeted magnetic hyperthermia.

KW - Cancer therapy

KW - Iron oxide nanoparticles

KW - Magnetic hyperthermia

KW - Magnetic nanoparticles

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85054931600&partnerID=8YFLogxK

U2 - 10.3389/fphar.2018.00831

DO - 10.3389/fphar.2018.00831

M3 - Review Article

VL - 9

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

M1 - 831

ER -